Assessment of cfDNA-STING Axis as a Potential Pathological Marker in Atopic Dermatitis
Recruiting now
Conditions studied: Atopic Dermatitis (Eczema)
In brief
Study Overview Atopic dermatitis (AD), commonly known as eczema, is a chronic inflammatory skin condition characterized by intense itching and skin barrier damage. While researchers know that the immune system is overactive in AD, it is difficult to measure the exact level of "damage" or "inflammation" happening deep within the skin using only a physical exam. The Purpose of This Study This study investigates a specific "danger signal" called circulating cell-free DNA (cfDNA). When skin cells are damaged or die due to inflammation, they release tiny fragments of DNA into the bloodstream. The investigators believe these fragments might act as a trigger for the immune system, worsening the disease. What the Study Involves Researchers will collect blood samples and small skin biopsies from patients with AD and healthy volunteers. The study aims to: Compare the levels of cfDNA in the blood of AD patients versus healthy individuals. Determine if higher levels of cfDNA correlate with more severe skin symptoms (measured by scores like SCORAD and EASI). Examine how immune cells in the skin (macrophages) respond to these DNA fragments through a specific biological switch called the STING pathway. Potential Impact By understanding this "damage-signal" loop, this research may lead to new ways for doctors to monitor AD severity through simple blood tests and could identify new targets for future anti-inflammatory treatments.
Key facts
- Study ID
- NCT07573735
- Run by
- Zhongda Hospital
- People needed
- 80
- Starts
- 2026-02-01
- Expected to finish
- 2026-07-31
- Last updated by the study team
- 2026-06-11
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Age 18 years or older
- Confirmed diagnosis of Atopic Dermatitis
You may not qualify if…
- Use of systemic immunosuppressants, systemic corticosteroids, or biological agents within 4 weeks prior to enrollment
- Use of topical treatments within 2 weeks prior to enrollment
Where it is running
- Zhongda Hospital, Southeast University — Nanjing, Jiangsu, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.